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ABSTRACT 
Human serum albumin (HSA) binds with fatty acids under normal physiological conditions. To date, 
there is little published information on the tertiary structure of HSA-fatty acid complex in aqueous 
solution. In the present study, we used molecular dynamics (MD) simulations to elucidate possible 
structural changes of HSA brought about by the binding of fatty acids. Both unliganded HSA and 
HSA-fatty acid complex models for MD calculations were constructed based on the X-ray crystal 
structures. Five myristates (MYRs) were bound in the HSA-fatty acid complex model. In the present 
MD study, the motion of domains I and III caused by the binding of MYR molecules increased the 
radius of gyration of HSA. Root mean square fluctuations from the MD simulations revealed that the 
atomic fluctuations of the specific amino acids at drug binding site I that can regulate the drug binding 
affinity were increased by the binding of MYR molecules. Primary internal motions, characterized by 
the first three principal components, were observed mainly at domains I and III in the principal 
component analysis for trajectory data. The directional motion projected on the first principal 
component of unliganded HSA was conserved in HSA-MYR complex as the third principal 
directional motion with higher frequency. On the other hand, the third principal directional motion in 
unliganded HSA turned into the first principal directional motion with lower frequency in HSA-MYR 
complex. Thus, the present MD study provides insights into the possible conformational changes of 
HSA caused by the binding of fatty acids. 
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INTRODUCTION 
Human serum albumin (HSA) is a major protein component of blood plasma. HSA serves as a 
transport for fatty acids and for a broad spectrum of therapeutic agents, and drug binding to HSA can 
result in a prolonged in vivo half-life of the drug. Thus, the binding properties of drugs to HSA is one 
of the most important factors determining their pharmacokinetics.1 
HSA consists of 585 amino acids and has a molecular mass of 66500 Da. The structure of 
HSA consists of three homologous domains (domains I-III), each of which is divided into two 
subdomains, A and B, having six and four α-helices, respectively.2-4 Multiple drug binding sites have 
been reported for these subdomains.1,5,6 Among the drug binding sites, two primary binding sites, site 
I (the warfarin binding site, located in subdomain IIA) and site II (the indole-benzodiazepine site, 
located in subdomain IIIA) have received particular attention because of their high-affinity drug 
binding.5 Detailed studies have been carried out on site I, including X-ray crystallography of 
HSA-warfarin complex7 and measurements of binding affinity at site I using recombinant HSA 
mutants.8,9 
When measuring the binding affinity of a drug to HSA in vitro, defatted HSA is usually used. 
On the other hand, under normal physiological conditions, HSA binds with approximately 0.1-2 
moles of fatty acid per mol protein.10 A number of studies on the effect of fatty acids on the drug 
binding affinity of HSA report that fatty acids may influence the drug binding affinity.11-15 
Additionally, X-ray crystal structures have been studied with respect to structural differences between 
unliganded HSA and HSA-myristate (HSA-MYR) complex.16,17 Although it is realized that solution 
and crystal structures of a protein are generally similar in most cases, the solution structure may not 
be equal to its crystal structure, which is influenced by the packing of proteins in a crystal.18 To date, 
little information has been published on conformational changes caused by the binding of fatty acids 
to HSA in aqueous solution. 
 X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy have been used 
to analyze the tertiary structures of macromolecules,19,20 and recently, molecular dynamics (MD) 
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simulations have also become a promising tool for the investigation of macromolecules. MD 
simulation gives insights into the natural dynamics on different timescales of macromolecules in 
solution, and affords thermal averages of molecular properties.21,22 There have been several MD 
simulation studies regarding HSA. MD simulations with a limited space around the Nξ atom of K199 
were carried out to investigate the influence of the protonation state of K195 and K199.23 Recently, an 
MD study dealing with the entire HSA molecule with explicit water molecules was also reported.24 
These studies provided useful information on the primary drug binding sites of HSA, however, 
directional motions among domains in unliganded HSA, and conformational changes brought about 
by the binding of fatty acids in aqueous solution have not yet been elucidated. 
The present study was undertaken to elucidate the entire HSA structure in aqueous solution 
based on MD simulations with explicit water molecules. Our study also aimed to elucidate 
conformational changes as well as changes in dynamics due to the binding of fatty acids. In this paper, 
we present the results of 10 ns MD simulations of unliganded HSA and HSA-fatty acid complex. It 
was found that the atomic fluctuations of the amino acids at site I that regulate the drug binding 
affinity increase upon binding of MYR molecules. In addition, the present study revealed that the first 
principal directional motion in unliganded HSA is weakened but still present as the third principal 
directional motion in HSA-MYR complex. These findings may be important in understanding the 
effects of MYR on the drug binding affinity of HSA. 
 
MATERIALS AND METHODS 
Tertiary structure of unliganded HSA and HSA-fatty acid complex 
 The initial coordinates of unliganded HSA and HSA-MYR complex were obtained from the 
Protein Data Bank (PDB)25 (unliganded HSA: PDB entry 1AO64; HSA-MYR: PDB entry 1BJ516). 
The resolution of the structure in each PDB entry was 2.5 Å. In PDB entry 1BJ5, five MYR molecules 
were bound to HSA (Fig. 1), and all were included in the following MD simulations. 
 
 5 
MD simulations of unliganded HSA and HSA-MYR complex 
 A series of MD calculations (simulation and trajectory analysis) were carried out using the 
AMBER7 package,26 using the LEaP module27 for model construction of unliganded HSA and 
HSA-MYR complex. The Sander module was used for energy minimization and MD calculations, 
and the AMBER94 force field28 was used for modeling the HSA system. The force field of MYR was 
generated by the antechamber module, based on the general AMBER force field (GAFF).29 
Following ab initio optimization of a MYR molecule at the HF/6-31G* level by Gaussian 03,30 
restrained electrostatic potential (RESP) was used as the charge method in GAFF. 
 Missing atoms were added to the initial coordinates by the LEaP module. Energy 
minimization with constraints on the positions of heavy atoms was carried out for 500 steps. Na+ 
counterions were placed by LEaP to neutralize the −15 (unliganded HSA) and −14 (HSA-MYR 
complex) charges of the HSA models at pH 7. A rectangular-shaped box of water was constructed 
using the TIP3 water model,31 with the buffering distance set to 12 Å. For the water box model, 500 
steps of energy minimization constraining the HSA molecule were carried out, followed by 500 steps 
of energy minimization with no constraints. 
 After energy minimization, 10 ns MD calculations were carried out for both the unliganded 
HSA and HSA-MYR complex models under periodic boundary conditions. The nonbonded list was 
generated using an atom-based cutoff of 8 Å. The long-range electrostatic interactions were handled 
by the particle-mesh Ewald algorithm.32 The time step of the MD simulations was set to 2.0 fs, and 
the SHAKE algorithm33 was used to constrain bond lengths at their equilibrium values. Temperature 
and pressure were maintained using the weak-coupling algorithm34 with coupling constants τT and τP 
of 1.0 ps and 0.2 ps, respectively (310 K, 1 atm). Coordinates were saved for analyses every 1 ps. The 
resultant model systems contained 87223 (unliganded HSA) and 99126 (HSA-MYR complex) atoms. 
 The present MD simulations were run on an in-house PC cluster composed of 8 nodes 
(Pentium® 4 2.4 GHz, 1 GB DDR memory) with a gigabit ethernet interconnection. Trajectory 
analyses were carried out using the ptraj and carnal modules. Structural diagrams were prepared by 
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Visual Molecular Dynamics (VMD; ver.1.8.3).35 
Principal component analysis for identifying global and correlated motions 
 Principal component analysis (PCA) is a powerful tool for finding global, correlated motions 
in atomic simulations of macromolecules.36,37 Briefly, PCA is carried out for collective coordinates 
from MD simulations. The collective coordinate matrix is a 3N × T matrix, where N is the number of 
atoms considered, and T is the number of the coordinate set collected by the simulations. The 
collected coordinate matrix can be used to construct a covariance matrix A, whose (i, j) component is 
defined as: 
   ( )( )ij i i j jA x x x x= − −     (1) 
where ...  is the average over the T sampled data and xi is a mass-weighted atomic coordinate. The 
diagonalization of A yields the eigenvectors and eigenvalues, which represent the components and 
magnitudes of atomic fluctuations, respectively. In a protein, a few modes contain more than half of 
the total fluctuation in the system, and the first few modes usually describe global, collective motions. 
To verify the relevance of the eigenvectors, the overlap38 between two sets of n orthonormal 
eigenvectors 1{ ,..., }nv v  and 1{ ,..., }nw w , was calculated as follows: 
   2
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To estimate how much of the major essential modes from the covariance analysis resemble random 
diffusion, its cosine content39 ci of the eigenvector i was calculated as follows: 
   ( ) ( )2 120 02 cos( ) ( ) ( )T Ti i ic i t p t dt p t dtT p
−
= ∫ ∫    (3) 
where pi(t) is the amplitude of the motion along eigenvector i at time t. The cosine content can take 
values between 0 (no cosine) and 1 (a perfect cosine), and provides an indicator of the extent of 
sampling. 
 A series of PCA calculations was carried out on the trajectory data of both unliganded HSA 
and HSA-MYR complex systems using the quasih module40 of the AMBER7 package. Directional 
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motion projected on each eigenvector was visualized by the interactive essential dynamics plug-in41 
in VMD. 
Entropy calculation from covariance matrices of the atomic fluctuations 
 The change in configurational entropy of HSA molecule by the binding of MYR was 
estimated from the results of the PCA for the mass-weighted covariance matrix A. The 
configurational entropy was calculated as follows42: 
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where kB, h, T, ωi are the Boltzmann constant, the Planck constant, the absolute temperature, and the 
quasiharmonic frequency ( B ik T λ= , λi : eigenvalue) for the i-th eigenvector, respectively. To 
estimate contributions to the change in the configurational entropy upon binding, the contribution 
ratio of the entropic cost in the binding free energy (=∆H−T∆S) was calculated as follows: 
   
T S
contribution ratio
H T S
∆
=
∆ + ∆
   (5) 
where ∆S and ∆H are the changes in the configurational entropy and the enthalpy of both HSA and 
MYR molecules, respectively. 
 
RESULTS AND DISCUSSION 
Root mean square deviation of unliganded HSA and HSA-MYR complex systems 
 The root mean square deviation (RMSD) from the X-ray structure provides a direct measure 
of the structural drift from the initial coordinates as well as the atomic fluctuation over the course of 
an MD simulation. The RMSD values of heavy atoms in unliganded HSA and HSA-MYR complex 
systems are shown in Fig. 2. In both systems, RMSD values reached plateau at about 2 ns (Fig. 2A). 
Calculated from the 2.5-10 ns trajectory data, the RMSD values of heavy atoms in the whole HSA 
molecule were 3.69 ± 0.35 Å and 3.42 ± 0.38 Å for unliganded HSA and HSA-MYR complex, 
respectively. Hence, we conclude that no significant structural drift from the X-ray structure occurred 
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during the MD simulations. 
 With respect to the RMSD of heavy atoms at drug binding site I (Fig. 2B), the RMSD values 
were 2.20 ± 0.12 Å for unliganded HSA and 2.23 ± 0.31 Å for HSA-MYR complex, calculated from 
the 2.5-10 ns trajectory data. These RMSD values were smaller than those of the whole HSA 
molecule, indicating that site I exhibited smaller atomic fluctuation; that is, site I is a relatively rigid 
region in the whole HSA molecule. The RMSD values of the other primary drug binding site, site II, 
were also small (2.19 ± 0.15 Å for unliganded HSA and 1.81 ± 0.13 Å for HSA-MYR complex, 
calculated from the 2.5-10 ns trajectory data). Thus, it was suggested that both primary drug binding 
sites I and II are relatively rigid. 
 
Radius of gyration of unliganded HSA and HSA-MYR complex systems 
 In the present MD studies, we determined the radius of gyration (Rg) as shown in Fig. 3. In 
both systems, Rg values reached plateau at about 2 ns, indicating that the MD simulations achieved 
equilibrium after 2 ns. The Rg value of HSA experimentally measured in aqueous solution is reported 
to be 27.4 ± 0.35 Å.43 In the present study, the Rg value of the unliganded HSA model was 27.20 ± 
0.23 Å, calculated from the 2.5-10 ns trajectory data. This coincidence indicates that the equilibrium 
state of HSA molecule in aqueous solution was well reproduced in the present MD studies. 
 The binding of MYR to HSA was found to increase the Rg of unliganded HSA in the present 
MD simulations (Fig. 3). Calculated from the 2.5-10 ns trajectory data, the Rg value of HSA-MYR 
complex was 28.28 ± 0.22 Å, larger than that of unliganded HSA. To clarify the origin of this increase 
in Rg upon binding to MYR, we conducted a comparison of the average structures of unliganded 
HSA and HSA-MYR complex using the 2.5 to 10 ns MD trajectory. Table I shows the RMSD in Cα 
atom positions after the superposition of the two averaged structures using residues in domain II or in 
individual domains. At domain II, little change was observed in the conformation of HSA by the 
binding of MYR molecules. On the other hand, a dramatic increase was observed in the relative 
motions of domains I and III, especially those of subdomains IA, IB, and IIIB. These observations are 
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consistent with those reported by Curry et al. in their X-ray crystal study.16 Thus, we expected to see 
the increase observed in Rg due to the binding of MYR molecules for HSA in aqueous solution (Fig. 
3) as well as in its crystalline state, and this increase was caused by the motions of domains I and III. 
 
Equilibrium fluctuations of unliganded HSA and HSA-MYR complex systems 
 Local protein mobility was analyzed by calculating the time-averaged root mean square 
fluctuation (RMSF) for each residue, based on the 2.5-10 ns trajectory data (Fig. 4). For comparison 
with experimental data, the B-factors of the X-ray crystal structure were converted to the equivalent 
RMSF values. The RMSF values of unliganded HSA (Fig. 4A) and HSA-MYR complex (Fig. 4B) 
were plotted against residue numbers. The general profiles of atomic fluctuations were found to be 
very similar to each other. It is worthwhile to note that, at drug binding sites I (subdomain IIA, 
residues 197-297) and II (subdomain IIIA, residues 384-497), the RMSF values in the MD studies 
were small compared with those of other regions (Fig. 4, Table II). Such profiles, i.e., smaller RMSF 
values at sites I and II, can be seen in both unliganded HSA (Fig. 4A) and HSA-MYR complex 
models (Fig. 4B). These results suggest that the structure of primary drug binding sites I and II 
remains rigid. However, this profile was not observed in the experimental RMSF values derived from 
B-factors. Considering the relatively low resolution of the X-ray structures (2.5 Å), it is likely that the 
B-factors in this case do not accurately reflect the thermal fluctuations of atoms. Thus, the present 
MD studies revealed the smaller atomic fluctuations at sites I and II, which may be characteristic of 
HSA molecule. 
 To investigate in detail the profile of the atomic fluctuation at drug binding site I, the RMSF 
value of each amino acid residue at the site was determined (Fig. 5). Here, we focused on mutated 
residues of HSA mutants belonging to site I, which have been reported to alter the binding affinity of 
site I drugs.8,9,44,45 Of these amino acid residues, K195, K199, R218, R222, H242 and H257 are 
positively charged residues which surround the entrance of the binding pocket of site I,4 while F211 
and W214 form the benzyl moiety in the binding pocket.7 In the present MD study, many of the 
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residues showed smaller RMSF values, suggesting that amino acids that can affect binding affinity in 
HSA molecules have very small atomic fluctuations; in other words, these amino acid residues are 
rigid as compared with other residues. 
 The effect of MYR binding to HSA on atomic fluctuations is shown in Table II. RMSF values 
at drug binding sites I (subdomain IIA) and II (subdomain IIIA) were not so much different. However, 
RMSF values of the specific amino acid residues were increased by the binding of MYR (Fig. 5), 
suggesting that the binding affinity of site I drugs can be changed by MYR binding. As reported 
previously,11,12,14,15 fatty acids at high concentrations regulate the drug binding affinity of HSA in a 
complex manner. Thus, we suggest that the changes in atomic fluctuation observed in the present MD 
study influence the binding affinity of drugs. 
 
Principal component analysis for analyzing correlated motions of unliganded HSA and 
HSA-MYR complex 
 In order to analyze the internal motions of the whole HSA molecule as well as those of each 
domain, PCA was carried out using the 2.5-10 ns trajectory data of Cα atoms. In the present analysis, 
all structures were least squares fitted on the position of Cα atoms at time 2.5 ns to remove overall 
translation and rotation. Fig. 6 shows the RMS fluctuations along the first 50 eigendirections (square 
roots of eigenvalues divided by mass-weight) of the covariance matrix derived from the unliganded 
and liganded HSA trajectory. Compared with the whole HSA molecule (Fig. 6A), RMS fluctuations 
along the eigendirections of the covariance matrix derived from the trajectory of drug binding site I 
were much smaller than those from the whole HSA (Fig. 6B), indicating that the internal motions at 
site I are much smaller than those of the whole HSA molecule. 
 To verify the relevance of the eigenvectors derived from the unliganded HSA and HSA-MYR 
complex models, we calculated the overlap between the subspaces spanned by the eigenvectors. The 
first 10 eigenvectors were adopted for analysis as representing the primary internal motions of the 
whole HSA molecule, whose contribution ratios were 79.8% and 82.6% for unliganded HSA and 
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HSA-MYR complex, respectively. Table III shows the overlap of the first 10 principal components 
between the subspaces of unliganded HSA and HSA-MYR complex spanned by the eigenvectors. 
The overlap value observed at the whole molecule between unliganded HSA and HSA-MYR 
complex was 0.476 for the first 10 principal components. In addition, the smaller the spatial region 
(the number of Cα atoms), the larger the overlap between unliganded HSA and HSA-MYR complex. 
This result indicates that, as a result of the binding of MYR to unliganded HSA, the interdomain 
motions were changed more than intradomain motions. 
 To analyze the primary internal motions in the whole HSA molecule in detail, we focused on 
the first three principal components (PCs), whose contribution ratios were much larger than those of 
the other PCs (41.3%, 14.2%, and 9.9% for the unliganded HSA model, respectively, and 47.2%, 
10.8%, 7.2% for the HSA-MYR complex model). Fig. 7 shows the fluctuations of Cα atoms 
projected on the first three principal components, PC1, PC2, and PC3. In both the unliganded HSA 
and HSA-MYR complex systems, fluctuations were smaller at domain II (residues 197-383), but 
larger at domain I (residues 5-196) and domain III (residues 384-582). Thus, the primary internal 
motions can be seen primarily at domains I and III. 
 We used the interactive essential dynamics plug-in41 to visualize the directions of motion 
projected on the principal components, PC1, PC2, and PC3 (Fig. 8). In both unliganded HSA and 
HSA-MYR complex systems, cooperative motions between domains I and III were observed on the 
three principal components. To check the similarity of the direction of motion, the inner product 
between each principal component was calculated (Table IV). The direction of motion projected on 
PC1 of unliganded HSA (PC1HSA) was very similar to that projected on PC3 of HSA-MYR complex 
(PC3HSA-MYR). The inner product between PC1HSA and PC3HSA-MYR showed a high absolute value of 
−0.635, indicating that vectors PC1HSA and PC3HSA-MYR are similar in direction. In addition, the inner 
product between PC3HSA and PC1HSA-MYR also showed a high absolute value of 0.592. On the other 
hand, the quasiharmonic frequency of the cooperative motion for each principal component, 
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calculated as B ik T λ , was not so much changed by the binding of MYR (Table IV). These results 
suggest that the PC1HSA directional motion observed in unliganded HSA was conserved in 
HSA-MYR complex as the PC3HSA-MYR directional motion with higher frequency, and that, on the 
other hand, the PC3HSA directional motion in unliganded HSA turned into the PC1HSA-MYR directional 
motion with lower frequency in HSA-MYR complex. Thus, the present MD study successfully 
elucidated differences in the first three principal directional motions between unliganded HSA and 
HSA-MYR complex. 
 Regarding PCA, Hess38,39 pointed out that the sampling is far from converged when the first 
few principal components resemble cosines. We calculated the cosine contents of the first three 
principal components obtained from the 2.5-10 ns trajectory data using Eq. 3.  The cosine contents, c1, 
c2, and c3 were 0.744, 0.072, 0.060 for unliganded HSA, and 0.530, 0.544, 0.009 for HSA-MYR 
complex. The cosine contents of the PC1 showed relatively high values, implying that the 
fluctuations of PC1 might be caused by random diffusion because of the insufficient sampling. 
However, as described previously, the directional motions of the first principal component (PC1HSA, 
PC1HSA-MYR) in HSA molecule were also observed as the directional motions of the third principal 
component (PC3HSA-MYR, PC3HSA), whose fluctuations are not likely to be caused by random 
diffusion from the view of the cosine content, c3. Therefore, we believe that PC1 directional motions 
(PC1HSA, PC1HSA-MYR) do not arise from a random diffusion. In addition, by increasing the sampling 
period, more conformational freedom could be extracted. Table V shows the subspace overlap of the 
first three principal components between the sections of the 2.5-10 ns trajectory. The overlap between 
the 2.5-ns subsets (2.5-5.0, 5.0-7.5, 7.5-10 ns) was low, but was relatively high between the 7.5-ns 
subset (2.5-10 ns) and each 2.5-ns subset. Although the way to get a full impression of the 
conformational freedom of HSA is to perform a longer MD simulation, a length more than 10 ns 
simulation for HSA is currently beyond our computational resources. 
 
Change in configurational entropy of unlinganded HSA by binding of fatty acid 
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 Ligand binding is often associated with losses in configulational entropy.46 In the present 
study, we estimated the change in configurational entropy by the binding of MYR to HSA from the 
principal component analysis. Table VI shows the configurational entropy calculated from Eq. 4. The 
configurational entropy of unliganded HSA became small by the binding of five MYR molecules. 
The magnitude of the entropic cost of HSA molecule, HSAT S∆ , was 7.6 kcal/mol (310 K), calculated 
from the result of the 2.5-10 ns trajectory, and the magnitude of the entropic cost of both HSA and five 
MYR molecules ( 5HSA MYRT S T S T S∆ = ∆ + ∆ ) was considered to be > 7.6 kcal/mol in the binding 
free energy. On the other hand, for the binding of one MYR molecule, the magnitude was reported to 
be 0.57 kcal/mol (298 K).47 Assuming that the magnitude of the enthalpic cost of one MYR binding 
is the same ( H= ∆ ) at each MYR binding site, the contribution ratios of the entropic cost in the 
binding free energy were calculated from Eq. 5 as 0.57 ( 0.57)H∆ +  and > 7.6 (5 7.6)H∆ +  for 
one MYR molecule and five MYR molecules, respectively. Although each sampling was not fully 
converged as described previously, the results suggest that increasing the number of MYR binding to 
HSA causes the increase in the ratio of entropic cost in the binding free energy. In fact, HSA binds 
with approximately 0.1-2 moles of fatty acid per mol protein under normal physiological condition.10 
In the point of the contribution ratio of the enthalpic and the entropic cost in the binding free energy, 
less than two fatty acid molecules may be favorable for the binding to HSA. 
 
CONCLUSION 
 In the present study, the effect of the binding of fatty acids on the tertiary structure of HSA in 
aqueous solution was discussed based on the results of MD simulations. The primary HSA drug 
binding sites, I and II, showed relatively small RMSF values on average. The flexibility of the 
specific amino acids at site I that can regulate the drug binding affinity was increased by the binding 
of MYR molecules. In PCA, primary internal motions, characterized by the first three principal 
components, were observed primarily at domains I and III. The first principal directional motion in 
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unliganded HSA was conserved in HSA-MYR complex as the third principal directional motion with 
higher frequency, while the third principal directional motion in unliganded HSA turned into the first 
principal directional motion with lower frequency in HSA-MYR complex. Thus, the present study 
unraveled possible conformational changes caused by the binding of MYR molecules to HSA. To 
estimate more strictly the tertiary structure of HSA under normal physiological conditions by MD 
simulations, however, more physiological information is required, such as the relative affinity of fatty 
acid binding sites, and the kind of fatty acids bound to HSA. Simulations over longer time periods are 
also preferable for further detail investigation of the effect of fatty acid binding. Nevertheless, the 
present MD study successfully provided insights on the tertiary structure of HSA-fatty acid complex 
in aqueous solution as a step toward elucidating HSA under normal physiological conditions. 
Specifically, the present study makes an important contribution to understanding the effect of the 
binding of fatty acids on conformational changes of HSA in aqueous solution. 
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Table I. Comparison of the average structures of unliganded human serum albumin (HSA) and 
HSA-myristate (HSA-MYR) complex in the MD simulations.a  
Domain RMSD (Å) Subdomain RMSD (Å) Overallb By domainc Overallb By subdomainc 
I [5-196] 10.8 (8.8) 2.4 (1.3) IA [5-107] 13.9 (10.7) 2.0 (1.3) 
   IB [108-196] 5.0 (5.9) 1.5 (1.0) 
II [197-383] 1.4 (0.8) 1.4 (0.8) IIA [197-297] 1.2 (0.9) 1.0 (0.8) 
   IIB [298-383] 1.5 (0.7) 1.3 (0.6) 
III [384-582] 4.1 (6.8) 1.9 (1.4) IIIA [384-497] 2.3 (3.3) 1.1 (1.0) 
   IIIB [498-582] 5.7 (9.6) 1.9 (1.4) 
 
aNumbers in round brackets are root mean square deviations (RMSDs) at the X-ray crystal structure 
between PDB entries 1AO6 and 1BJ5, as previously reported by Curry et al.16 
bRMSD in Cα atom positions between domains after the superposition of the two molecules using the 
residues in domain II. 
cRMSD in Cα atom positions after superposing the individual domains from the unliganded HSA and 
HSA-MYR complex structures. 
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Table II. Root mean square fluctuation of Cα atoms (Å) for the whole HSA molecule, and for 
subdomains IIA and IIIA. 
 Whole molecule Subdomain IIA Subdomain IIIA 
Unliganded HSA 1.53 1.05 1.30 
HSA-MYR complex 1.65 1.07 1.36 
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Table III. Overlap of the first 10 principal components between the subspaces of unliganded HSA 
and HSA-MYR complex spanned by the eigenvectors.  
 No. Atomsa Overlapb 
Whole molecule 578 0.476 
Domain I 192 0.542 
 II 187 0.550 
 III 199 0.565 
Subdomain IA 103 0.506 
 IB  89 0.643 
 IIA 101 0.630 
 IIB  86 0.647 
 IIIA 114 0.595 
 IIIB  84 0.651 
 
aNumber of Cα atoms used for the principal component analysis. 
bOverlap between the subspaces spanned by the eigenvectors, as calculated by Eq. 2. 
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Table IV. Inner product between the first three principal components of unliganded HSA and 
HSA-MYR complex.a 
 PC1HSA-MYR 
(5.29 cm−1) 
PC2HSA-MYR 
(11.04 cm−1) 
PC3HSA-MYR  
(13.55 cm−1) 
PC1HSA (5.81 cm−1) 0.296 −0.368 −0.635 
PC2HSA (9.92 cm−1) 0.011 0.332 0.100 
PC3HSA (11.84 cm−1) 0.592 0.259 −0.072 
 
aNumbers in round brackets are the quasiharmonic frequency, calculated as B ik T λ , where λi, kB, T 
are the eigenvalue for the principal component i, the Bolzmann constant, and the absolute 
temperature, respectively. 
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Table V. Overlap of the first three principal components between the sections of the 2.5-10 ns 
trajectory.a 
Unliganded HSA 2.5-5.0 ns 5.0-7.5 ns 7.5-10 ns 2.5-10 ns 
2.5-5.0 ns 1 0.457 0.361 0.547 
5.0-7.5 ns  1 0.408 0.603 
7.5-10 ns   1 0.590 
2.5-10 ns    1 
HSA-MYR complex 2.5-5.0 ns 5.0-7.5 ns 7.5-10 ns 2.5-10 ns 
2.5-5.0 ns 1 0.471 0.589 0.697 
5.0-7.5 ns  1 0.555 0.572 
7.5-10 ns   1 0.810 
2.5-10 ns    1 
 
aOverlap is calculated by Eq. 2.
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Table VI. Configurational entropy of unliganded HSA and HSA-MYR complex estimated from the 
result of the principal component analysis.a 
Sampling SHSA SHSA-MYR ∆SHSA 
2.5-5.0 ns 0.711 0.707 −0.004 
2.5-7.5 ns 0.776 0.760 −0.016 
2.5-10 ns 0.818 0.793 −0.025 
 
aConfigurational entropy (S) is calculated by Eq. 4. All entropies are in kcal/mol ⋅ K.
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Figure Legends 
Fig. 1. Ribbon model of human serum albumin-myristate (HSA-MYR) complex derived from 
X-ray crystallography (PDB entry 1BJ516). HSA is composed of three homologous domains I-III. 
Each domain is divided into two subdomains, A and B. The five MYR molecules are shown in black 
in a space-filling representation. This diagram was generated using VMD.35 
Fig. 2. Time evolution of the root mean square deviation (RMSD) of heavy atoms from the starting 
structure during 10 ns molecular dynamics (MD) simulations of unliganded HSA and HSA-MYR 
complex models. RMSD values reached plateau at about 2 ns. A: all heavy atoms; B: heavy atoms 
belonging to drug binding site I (subdomain IIA). 
Fig. 3. Time evolution of the radius of gyration (Rg) during 10 ns MD simulations of unliganded 
HSA and HSA-MYR complex. Rg values reached plateau at about 2 ns. 
Fig. 4. Comparison of the root mean square fluctuation (RMSF) of Cα atoms along the sequence 
derived from the 2.5-10 ns MD simulations (solid line) and X-ray crystal structure (thin line). RMSF 
values derived from the X-ray crystal structure were calculated as 23 (8 )B p , where B is the 
temperature factor (B-factor) listed in the PDB files. At drug binding sites I and II, the RMSF values 
in the present MD studies were small compared with those of other regions. A: unliganded HSA; B: 
HSA-MYR complex. 
Fig. 5. Root mean square fluctuation (RMSF) of Cα atoms at drug binding site I. The amino acids 
whose mutations affected binding affinity at drug binding site I are also shown. Many of these amino 
acids showed smaller fluctuations. 
Fig. 6. Root mean square fluctuation along the eigendirections (square-roots of eigenvalues divided 
by mass-weight) of the coordinate covariance matrix constructed from Cα atoms of unliganded HSA 
and HSA-MYR complex. The fluctuations of drug binding site I were much smaller than those of the 
whole HSA molecule. A: all Cα atoms; B: Cα atoms belonging to drug binding site I.  
Fig. 7. Root mean square fluctuation of Cα atoms on the first, second, and third principal 
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components (PC1, PC2, PC3). The contribution ratio of each principal component is shown in round 
brackets. The atomic fluctuation is larger primarily at domains I and III. 
Fig. 8. Directional motions projected on the first, second, and third principal components. The 
arrows in the figure indicate the approximate directions of cooperative motions observed by 
interactive essential dynamics. The directional motion projected on PC1 of unliganded HSA was 
similar to that projected on PC3 of HSA-MYR complex (the inner product between PC1HSA and  
PC3HSA-MYR was equal to −0.635).  
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